What it's for (Indications)
- Estradiol valerate is primarily indicated for hormone replacement therapy (HRT) in postmenopausal women to alleviate moderate to severe vasomotor symptoms (e.
- g.
- , hot flashes, night sweats) associated with menopause.
- It is also utilized for the treatment of genitourinary syndrome of menopause (GSM), which encompasses symptoms such as vaginal dryness, itching, and dyspareunia, resulting from vulvovaginal atrophy.
- Furthermore, it is prescribed for the prevention of postmenopausal osteoporosis in women at a significant risk of fractures, especially when non-estrogen medications are deemed inappropriate or insufficient.
- In specific clinical contexts, estradiol valerate may be used to manage conditions like female hypogonadism or primary ovarian failure.
- It is important to note that when estradiol valerate is administered to women with an intact uterus, it is generally combined with a progestogen to counteract the proliferative effects of estrogen on the endometrium, thereby reducing the risk of endometrial hyperplasia and carcinoma.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For postmenopausal women with a uterus, progestin should be co-administered to reduce the risk of endometrial cancer; progestin is not needed for women without a uterus. Estradiol valerate, alone or in combination with a progestin, should be used at the lowest effective dose and for the shortest duration consistent with treatment goals and individual risks. Patients require periodic reevaluation (e.g., every 3 to 6 months) to assess the continued necessity of treatment. For women with a uterus, adequate diagnostic measures, including endometrial sampling, should be performed to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding. The medication should be injected deeply into the upper, outer quadrant of the gluteal muscle with usual intramuscular administration precautions. |
Safety & Warnings
Common Side Effects
- Common side effects may include nausea, vomiting, weight gain, breast tenderness and enlargement, rashes, and chloasma (skin discolouration).
- More serious adverse reactions reported include liver function disorders, jaundice, changes in vaginal bleeding patterns (abnormal withdrawal bleeding or flow, breakthrough bleeding, spotting), dysmenorrhea, increase in size of uterine leiomyomata, vaginitis (including vaginal candidiasis), changes in cervical secretion and ectropion, ovarian cancer, endometrial hyperplasia, and endometrial cancer.
Serious Warnings
- Black Box Warning: ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER. Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of "natural" estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses.
- Patients with hypertension, asthma, varicose veins, or epilepsy should take special precautions and consult their doctor.
- Consultation with a doctor is essential for patients with hormone-dependent tumours of the uterus or breasts, liver tumours, or endometriosis.
- Close clinical surveillance of all women taking estrogens is important, with adequate diagnostic measures, including endometrial sampling when indicated, to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding.
- Patients should be reevaluated periodically (e.
- g.
- , 3-month to 6-month intervals) to determine if treatment is still necessary.
How it Works (Mechanism of Action)
Estradiol valerate is a synthetic ester of 17β-estradiol, functioning as a prodrug. Upon oral administration, it undergoes rapid hydrolysis, primarily within the gastrointestinal tract and liver, to release its active form, 17β-estradiol. 17β-estradiol is the most potent and physiologically relevant endogenous estrogen. Its mechanism of action involves binding to specific, high-affinity estrogen receptors (ERα and ERβ), which are predominantly located within the cytoplasm and nucleus of target cells across a wide range of tissues, including the reproductive tract, mammary glands, bone, cardiovascular system, and central nervous system. Upon ligand binding, the estrogen receptors undergo a conformational change, dimerize, and translocate to the nucleus, where they bind to specific DNA sequences known as estrogen response elements (EREs) in the promoter regions of target genes. This binding modulates gene transcription, leading to the synthesis of specific proteins responsible for the diverse physiological effects of estrogen, such as the maintenance of bone density, regulation of the menstrual cycle, and the development and maintenance of female secondary sexual characteristics. By replacing deficient endogenous estrogen, estradiol valerate effectively mitigates the various symptoms associated with estrogen deficiency, particularly those observed during menopause.
Commercial Brands (Alternatives)
No other brands found for this formula.